Differentiation of B cell into immunoglobulin-producing plasma cell

The *differentiation of B cell into immunoglobulin-producing plasma cell* refers to the final stage in B lymphocyte development where activated mature B cells become highly specialized effector cells called plasma cells. This transformation occurs after antigen encounter—often with T-cell help—and involves upregulation of key transcription factors such as IRF4 and BLIMP1. Plasma cells are responsible for secreting large quantities of antibodies that mediate humoral immune responses essential for defense against extracellular pathogens. The regulation involves complex signaling networks including cytokines like IL‑4, IL‑5, TGF‑β, IFN‑γ; defects can result in immune deficiency or contribute to autoimmunity when dysregulated[1][3][5][7]. Drugs such as belimumab target upstream regulators like BLyS/BAFF to modulate this process therapeutically in diseases such as systemic lupus erythematosus.

Other names

Plasma cell differentiationB cell maturation into plasma cellAntibody-secreting cell formation

Drugs like belimumab act by: - Binding BLyS/BAFF to reduce its activity. - Inhibiting survival signals for mature B cells. - Reducing the number of new plasma cells formed and thus lowering autoantibody production in diseases like SLE[4][6].